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Varicella-zoster virus vaccination under the 
exogenous boosting hypothesis: two ethical 
perspectives 
 
Abstract: The varicella-zoster virus (VZV) causes two diseases: varicella (‘chickenpox’) and herpes 
zoster (‘shingles’). VZV vaccination of children reduces exposure to chickenpox in the population and 
it has been hypothesized that this could increase the prevalence of shingles. This ‘exogenous 
boosting’ effect of VZV raises an important equity concern: introducing a vaccination program could 
advance the health of one population group (children) at the expense of another (adults and elderly). 
We discuss the program’s justifiability from two ethical perspectives, classic utilitarianism and 
contractualism. Whereas the former framework might offer a foundation for the case against 





The varicella-zoster virus (VZV) causes two distinct diseases: varicella  (i.e. “chickenpox”) 
and herpes zoster (i.e. “shingles”) (Gershon, Takahashi et al. 2008). Chickenpox, which 
primarily occurs during childhood, causes an itchy rash for about a week. Complications from 
chickenpox are relatively infrequent and include pneumonia, bacterial surinfection and 
encephalitis. Shingles predominantly occurs at older age. It is the result of a reactivation of 
VZV, which after chickenpox remains latently present in neural ganglia. This reemergence of 
the virus can be assumed to be a consequence of waning cellular immunity. Shingles is 
characterized by a painful rash on the body and causes on average a more severe and 
longer-lasting loss of quality of life than chickenpox (Bilcke, Ogunjimi et al. 2012).  
 
Already in 1965 it was postulated that occasional re-exposure to VZV through chickenpox 
could boost VZV-specific immunity of adults, and consequently avoid reactivation of VZV 
(Hope-Simpson 1965). Older generations may thus require the occasional proximity of 
children infected with VZV in order to keep their protection against shingles up to date. A 
consequence of this so-called “exogenous boosting hypothesis” would be an increase in 
shingles cases in the decades following the introduction of a universal childhood chickenpox 
(or VZV) vaccination program. Indeed, many simulation studies on the incidence of VZV 
predicted an increase in shingles incidence after introduction of widespread childhood 
chickenpox vaccination due to the loss of protection from exposure to chickenpox [e.g. 
(Schuette and Hethcote 1999; Brisson, Edmunds et al. 2000; Van Hoek, Melegaro et al. 
2012; Bilcke, van Hoek et al. 2013)]. A systematic review of the scientific literature on 
shingles risk reduction through chickenpox exposure concluded that exogenous boosting 
exists, although the true effect size is yet to be determined (Ogunjimi, Van Damme et al. 
2013).  
 
Evidently, this vaccination program raises an equity concern: the health prospects of one 
population group could be advanced to the detriment of another group. Several countries 
(e.g. USA, Germany, Australia, Japan, Taiwan, Greece) have introduced widespread 
childhood vaccination against chickenpox (Ogunjimi, Van Damme et al. 2013). Many others 
are considering doing the same thing but are awaiting more conclusive data on the duration 
and magnitude of the exogenous boosting effect. However, the program’s justifiability cannot 
only be determined by data. This, as several researchers have urged, also requires ethical 
discussion (Taylor 2001; Beutels, Scuffham et al. 2008; Luyten, Vandevelde et al. 2011; 
Bilcke, Van Hoek et al. 2013). Nonetheless, hitherto, in-depth analysis remains lacking from 
the literature.  
 
The VZV issue cannot be settled by simply adhering to fixed ethical rules such as respecting 
autonomy (to become vaccinated) or ‘do no harm to others’ (i.e. do not become vaccinated). 
It necessitates balancing of different groups’ competing basic interests and therefore it 
requires a more complex ethical framework. The objective of this paper is to structure and 
clarify ethical reflection on the issue by framing it from two fundamental ethical perspectives: 
classic utilitarianism and contractualism. Whereas there exist other perspectives from which 
the issue can be approached, in our opinion the two perspectives we discuss give an intuitive 
and consistent foundation to the case pro and contra. The first framework, classic 
utilitarianism, would, in the present state of knowledge on VZV-related risks, serve as a 
normative basis to oppose childhood vaccination. The second framework, contractualism, is 
a completely different ethical starting point. It offers a foundation to argue why childhood VZV 
vaccination would be justified. 
 
We do not discuss here whether VZV vaccination is a good use of health care resources. 
Whether the program is cost-effective or not, and whether cost-effectiveness warrants 
funding or not, is a more general issue of resource allocation, which is not of particular 
relevance to this specific ethical dimension of VZV vaccination (i.e. the redistribution of 
disease between the age groups affected by the program). Instead we will only consider the 
health effects of implementing the program.  
 
 2. Utilitarianism 
 
 From the 18th century onwards, largely through the works of philosophers such as Bentham, 
Mill and Sidgwick, utilitarianism became a highly influential theoretical framework that was 
able to approach complex societal issues in a transparent and straightforward way (Kymlicka 
1990). Up to today it has had a profound impact on both ethical discourse and public policy. 
By now there exist many interesting versions and adaptations of utilitarianism, (see e.g. 
(Sinnott-Armstrong 2014)) but in its most classic form it starts from two premises: : (1) when 
difficult ethical decisions need to be made, ultimately, the available choice-alternatives’ effect 
on wellbeing (or one of its related forms, e.g. happiness or health) is the only aspect that 
really matters and (2) everyone’s wellbeing is equally important. Consequently, policy 
choices are justifiable depending solely on the fact whether they – compared to the 
alternatives - contribute most to total (or average) wellbeing. It appeals to the intuition that 
wellbeing (or in our case health) is of such an essential importance that it should not be 
‘wasted’ by choosing for suboptimal courses of action, motivated by e.g. misguided moral 
principles, intentions or religious beliefs.  
 
In the specific case of VZV, the relevant ethical question from a classic utilitarian perspective 
is thus whether introducing childhood chickenpox vaccination diminishes the total burden of 
disease. Existing empirical evidence from the USA shows that universal chickenpox 
vaccination is a success related to chickenpox: hospitalisation reduction up to 88%, mortality 
reduction more than 74% (Marin, Meissner et al. 2008). However, such assessments are 
partial, as they exclude the shingles-effects in adults and the elderly. The exact magnitude of 
the exogenous boosting effect is still a matter of discussion (Ogunjimi, Van Damme et al. 
2013). Nonetheless, several modeling studies have indicated that chickenpox vaccination is 
not attractive anymore after accounting for the redistributive effect on older generations. 
Brisson and Edmunds estimated that routine infant vaccination against chickenpox will 
produce an increase in overall morbidity in England and Wales, as the QALYs lost to 
shingles (induced by exogenous boosting) are greater than those won by averting 
chickenpox (Brisson and Edmunds 2003). These findings were confirmed in later studies that 
also use QALYs as an outcome (not with life-years gained as an outcome) (Bilcke, Van Hoek 
et al. 2013). Shingles vaccination of older adults could only in some scenarios fix this 
problem and yield gains in total net QALYs (Bilcke, Van Hoek et al. 2013) (Van Hoek, 
Melegaro et al. 2012). 
 
The overall potential negative health impact of a universal childhood vaccination program 
raises serious questions about the program’s net effect on wellbeing. The ethical objection 
against this is coherently expressed through a classic utilitarian perspective. Awaiting more 
conclusive evidence, it would offer a basis to prescribe policy measures that limit or 





Contractualism is a completely different ethical approach and it offers a different perspective 
on the VZV-case. Again, many influential variants exist (Kymlicka 1990), ranging from 17-
18th century theories from philosophers such as Hobbes, Locke and Rousseau to late 20th 
century authors such as Rawls (Rawls 1971) or Scanlon (Scanlon 1998). From the 
contractualist viewpoint, the moral justifiability of a decision is not determined by weighing 
consequences (e.g. health effects), but by its justifiability in terms of principles and rules, 
resulting from a hypothetical ‘social contract’. This contract is laid out between all individuals 
and in this they decide which fundamental rules ought to govern society. Requirements for 
establishing the contract are that the agreement is made between equals in power (freedom 
from domination) and that contracting parties are rational and reasonable. If so, they can 
come to a consensus about which rules and arrangements are fair and acceptable, and 
which ones not. This initial contract serves as a moral benchmark to evaluate policy options 
and measures.  
 
If we apply such a contractualist perspective to the VZV problem, the relevant issue is not 
whether the aggregate benefit of the vaccination program quantitatively outweighs the 
required sacrifice, but whether its introduction can be justified in terms of universally-
acceptable principles, i.e. principles that are also acceptable to those who stand to lose: the 
adults and the elderly. The following considerations would become relevant.  
 
Freedom and responsibility. Contractants would grant each other extensive autonomy, 
especially in matters of the body and health. This entails the freedom to protect one’s own 
health by becoming vaccinated. Moreover, if those who risk to undergo the negative 
externalities of a chickenpox vaccination program (adults and elderly) can be expected 
capable of protecting themselves, e.g. by becoming vaccinated against shingles themselves, 
but refuse or neglect to do so, their demand for solidarity may lose universal appeal. 
Shingles vaccination of elderly reduces shingles’ incidence by 50% and its burden of disease 
by 60% in adults aged 60 years and older (Oxman, Levin et al. 2005; Schmader, Oxman et 
al. 2012). Importantly, shingles vaccination can be deemed safe (Oxman, Levin et al. 2005). 
 
Unacceptable sacrifices. Reasonable contractants would never agree on a principle that 
justifies big losses concentrated in a small number of individuals in exchange for a benefit 
spread out thinly over a large group. This is a main point where contractualism differentiates 
itself from utilitarianism [for discussion of this point, see e.g. (Rawls, 1971, p. 19-30)]. In the 
VZV case, some members of older generations will not be able to protect themselves against 
shingles (because of ineffective vaccine, medical reasons to avoid vaccinations, etc.). These 
individuals would be ‘sacrificed’ for the benefit of a large group of children. However, the 
difference in severity between shingles and chickenpox might not be big enough to call this 
sacrifice an unreasonable demand. Despite shingles presenting on average a more severe 
clinical image than chickenpox, the effects are only rarely leading to fatalities or permanent 
disability (Bilcke, Ogunjimi et al. 2012). In other contexts (e.g. traffic, energy-use, food safety) 
similar risks are often considered acceptable. 
 
Uncertainty. An impartial contractor will value prudence and risk-aversion, especially in 
health matters. Although the literature suggests that exogenous boosting exists, its effects on 
the incidence of shingles remain more uncertain than the effects of vaccination on the 
disease burden of chickenpox. If a preventive program will produce protection with (close to) 
certainty, but has uncertain externalities, then it seems reasonable to demand a more 
favourable weighing of those health outcomes of which we can be sure and to discount those 
with more uncertainty. This speaks in favour of vaccinating children, as here uncertainties 
are lower.  
 
Age. Some authors argue that age can be a “morally-relevant” personal characteristic in 
setting health priorities (Callahan, 1987, Daniels 1988; Williams 1997). However, in the 
present context, we would judge that an impartial person would not consider VZV-related 
disease occurring in children as intrinsically more valuable than disease occurring in older 
generations. The negative effects of chickenpox vaccination on shingles incidence would 
already occur in young individuals, far below a possible threshold to speak of a ‘fair innings’ 
(Williams, 1997), i.e. an age after which someone may be considered as having received 
his/her fair share of life. Moreover, VZV infections rarely lead to permanent disability or 
mortality but mostly to transient illness, which is less relevant for a fair innings argument. In 
fact, one might even speculate that young individuals have more resilience in coping with 
physical annoyances than old people. 
 
Acts and omissions. A final consideration may be that letting VZV infections run their natural 
course leads to harm resulting from an omission (not introducing vaccination) whereas 
changing the natural epidemiology by introducing childhood chickenpox vaccination causes 
harm that is more ‘man-made’ or ‘policy-induced’. People indeed judge harms following from 
actions and omissions differently (Spranca, Minsk et al. 1991) and also in ethics the duty of 
avoiding actions that bring harm is often held to be stronger than the duty of doing good 
(Beauchamp and Childress 2001). However, in this case the nuance seems to be of lesser 
relevance. First, redistributing health risks from children to older generations through 
vaccination could still qualify as an omission (allowing harm to occur) rather than as an act of 
doing harm. Second, a preference for the ‘natural’ epidemiology of VZV over an ‘artificial’ one 
is based upon a contestable and non-universally shared metaphysical view about nature, i.e. 
about the moral value and authority of its natural order.   
 
These considerations allow us to frame the VZV vaccination issue from a different 
perspective than the utilitarian one. If we force ourselves to think in terms of a social contract, 
the case against chickenpox vaccination for children becomes unconvincing. It is hard to 
motivate with principles why children should protect older generations through experiencing 
chickenpox instead of protecting themselves through vaccination. The fact that adults and 
the elderly can to a substantial extent avoid shingles infection themselves, that risks of 
disability and mortality from shingles remain all-in-all relatively limited and that the effect size 
of exogenous boosting remains uncertain are important arguments to the benefit of children. 
Arguments about age and about the natural vs. man-made origins of VZV-infections are 
open for discussion, but even if they would be to the advantage of older generations they 





Evidence increasingly suggests that chickenpox vaccination of children risks redistributing 
health risks towards older generations. Next to a need for more conclusive data, there is also 
a need for further ethical discussion on the justifiability of this program. We discussed the 
case pro and contra widespread childhood chickenpox vaccination from two different ethical 
perspectives. In the current state of knowledge on VZV, classic utilitarianism, highlighting 
aggregate health and wellbeing, seems to support the case against introducing universal 
childhood chickenpox vaccination because the exogenous boosting effect on older 
generations would outweigh the total health benefits of the program for children (when it is 
valued in QALYs). However, this claim is largely based upon the yet available empirical 
studies and new evidence on the effect size of exogenous boosting effects could alter this 
conclusion. The contractualist view, however, highlights impartial a priori rules instead of a 
posteriori consequences, and is therefore less dependent on quantitative estimates of 
consequences. This perspective offers a basis to justify the introduction of a chickenpox 
program for children. We conclude that discussions, and eventually decisions on VZV-policy 
not only require using quantitative data (e.g. studies estimating the effect size on disease 
burden) but that they also require specification of the ethical framework in which terms the 
discussion is implicitly held, and consideration and discussion of alternative ethical 
perspectives.   
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